BlackRock Amends Jazz Pharma Stake, Signals Continued Confidence
Ticker: JAZZ · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1232524
| Field | Detail |
|---|---|
| Company | Jazz Pharmaceuticals PLC (JAZZ) |
| Form Type | SC 13G/A |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still holds Jazz Pharma stock, signaling stability.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating its ownership of Jazz Pharmaceuticals plc's Common Stock as of December 31, 2023. This filing, an amendment to a previous one, shows BlackRock's continued significant, but passive, stake in Jazz Pharmaceuticals. This matters to investors because BlackRock is a major institutional investor, and its sustained position suggests a long-term, stable outlook on Jazz Pharmaceuticals' value, potentially signaling confidence in the company's future performance.
Why It Matters
This filing confirms BlackRock, a major institutional investor, maintains a significant passive stake in Jazz Pharmaceuticals, which can be seen as a vote of confidence in the company's long-term prospects.
Risk Assessment
Risk Level: low — This filing is routine for large institutional investors and does not indicate any immediate or significant risk to the company or its shareholders.
Analyst Insight
An investor might view BlackRock's continued passive ownership as a sign of stability and long-term confidence in Jazz Pharmaceuticals, potentially reinforcing a decision to hold or consider buying the stock.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Jazz Pharmaceuticals plc (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the date the SC 13G/A was filed
Forward-Looking Statements
- BlackRock will maintain a significant, passive stake in Jazz Pharmaceuticals plc for the foreseeable future. (BlackRock Inc.) — high confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and '(Amendment No: 2)' in the filing.
Who is the 'subject company' in this filing?
The subject company is Jazz Pharmaceuticals plc, identified by 'COMPANY CONFORMED NAME: Jazz Pharmaceuticals plc' and 'Name of Issuer: JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY'.
Who is the 'filed by' entity in this document?
The entity that filed this document is BlackRock Inc., as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.'.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which required the filing of this statement was December 31, 2023, as explicitly stated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' next to '[X] Rule 13d-1(b)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding Jazz Pharmaceuticals plc (JAZZ).